Pfizer is paying $650 million in upfront cash and making a $350 million equity investment in Arvinas, with another $1.4 billion in backloaded milestone payments.

Pfizer has revealed that its much-anticipated ... Topline results from the VERITAC-2 study showed that Arvinas-partnered vepdegestrant was able to extend progression-free survival (PFS) compared ...

and NEW YORK, March 11, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 VERITAC-2 clinical trial NEW ...

Novo Nordisk, Roche, Pfizer, Arvinas and J&J are part of the Zacks top Analyst Blog. With Roche's latest deal, a new contender enters the obesity space, which could threaten NVO and LLY's ...

ARV-102 is Arvinas’ investigational PROteolysis TArgeting Chimera (PROTAC) degrader targeting leucine-rich repeat kinase 2 (LRRK2), a multifunctional protein that has been implicated in Parkinson’s ...

(Reuters) - Pfizer (NYSE:PFE) has invested $25 million to buy a minority stake in Caribou Biosciences, making it the latest... ByReuters • Jul 06, 2023 Caribou Bioscience Climbs 67% Following ...